Cost-Utility of Nivolumab Plus Ipilimumab in First-Line Treatment of Advanced Melanoma in the United States: An Analysis Using Long-Term Overall Survival Data from Checkmate 067

OBJECTIVE: The aim of this study was to evaluate the cost-utility of nivolumab plus ipilimumab (NIVO + IPI) versus other first-line therapies for advanced melanoma in the United States (US) from the third-party payer perspective. METHODS: This analysis estimated total expected life-years (LYs), qual...

Descripción completa

Detalles Bibliográficos
Autores principales: Baker, Timothy, Johnson, Helen, Kotapati, Srividya, Moshyk, Andriy, Hamilton, Melissa, Kurt, Murat, Paly, Victoria Federico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9440167/
https://www.ncbi.nlm.nih.gov/pubmed/36006606
http://dx.doi.org/10.1007/s41669-022-00348-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9440167/
https://www.ncbi.nlm.nih.gov/pubmed/36006606
http://dx.doi.org/10.1007/s41669-022-00348-0

Ejemplares similares